Please provide your email address to receive an email when new articles are posted on . An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leading AI-driven health technology and nference portfolio company working in collaboration with Mayo Clinic, today announced U.S. Food and Drug ...
Eko Health received FDA clearance this week for a new AI-powered tool that aids in the early detection of low ejection fraction, a key indicator of heart failure. About 6.2 million Americans battle ...
August 12, 2011 — Older patients are more likely than younger patients with a similar low left ventricular ejection fraction to have cognitive decline, report researchers. "Cognitive dysfunction due ...
Personalized gene expression profiling-guided (MAGE) therapy in resistant sarcomas. Preliminary data. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not ...
Physician-scientists at The Texas Heart Institute announced today the results of the largest cell therapy trial to date in patients with chronic heart failure due to low ejection fraction. The therapy ...
Allogeneic immunotherapy by hematopoietic stem cell transplantation (ASCT) after reduced intensity conditioning (RIC) following high-dose chemotherapy for patients with acute myeloblastic leukemia ...
Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients at risk of heart failure CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results